Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
about
Etrolizumab for induction of remission in ulcerative colitisEtrolizumab for induction of remission in ulcerative colitisRate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesCrohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative ColitisComparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab.Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice.Biologic agents for IBD: practical insights.Optimizing biological therapy in Crohn's disease.Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.Positioning ustekinumab in Crohn's disease: from clinical evidence to clinical practice.Top-down approach to biological therapy of Crohn's disease.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.Ustekinumab: A Review in Moderate to Severe Crohn's Disease.Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease.The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis.Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.Systematic review and network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.Optimization of biologic therapy in Crohn's disease.Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease.Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease.Evidence-based clinical practice guidelines for inflammatory bowel disease.Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project.Approach to Optimize Anti-TNF-α Therapy in Patients With IBD.Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay.Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.
P2860
Q24186788-C83DBAB0-D31A-4654-A363-FB9677BEABABQ24187269-C381CDA8-AAD6-4B24-8F03-052F5EAE3114Q26778600-27B5D57F-75FD-4E0A-A8F4-4FA7EBA26B59Q35933419-315CFF2C-AA07-443A-A440-E19B8C06862CQ36173188-1487C204-30F4-4F01-ADB0-3A49FCF1EC5AQ37029359-881F5BFB-3587-4E57-90ED-CD98706036CEQ37081907-AC9C5991-7499-473D-930A-E7AC18A3CF21Q38425123-905844AB-5B13-41E9-A60A-743805EC476BQ38568898-8B122986-2D43-4FCA-B607-245DD4138402Q38608158-8001822E-E89A-48F3-91D9-A7DA5F7FFF4BQ38619950-26D2B8CA-3B71-423A-8DBF-1B72CB6BB63FQ38652276-AC3B7184-E365-4765-8CC3-25AF0F7AA277Q38673082-CBD5285B-223A-42D2-AB1E-975C8DAB80DAQ38696735-57F836D5-886E-4DDF-B91B-D6F577B8C7E4Q38748380-4E22BA82-BB3D-411B-ADBF-F26BD530A9F9Q38764671-0B03C441-942C-4EB1-8EB5-B33C5CD9F351Q38822920-962EF891-4E8B-41A4-857C-E6288D3779A3Q38824505-CDA888CB-7EBA-4BC9-8D29-4DDAE268279AQ38865053-54A60B77-AA88-4B37-AC7A-5F7A70D85AB3Q39306418-33408C49-7538-427E-A570-E1C1208E9F7DQ39320474-FD797926-94E8-4260-BC01-F862DCA8EE47Q39419343-B206C61C-A9A7-4195-89F7-3C8903E0C6FFQ40703329-0A12B43C-95B1-4FD8-A8DF-2BD807AD6C26Q40722978-3B4D56AC-7437-4193-BFF3-874EFBC94199Q41160241-82E8AC82-FF13-40EE-B04E-33E4960FE7DBQ42321851-73B1EBFF-F10B-4B42-96BB-343411D2D476Q46070749-F0C5F487-7492-482B-B3BC-3EB21C6B71AEQ46345854-6EADB798-3032-4FB0-8E22-50E893D36384Q47389870-8795A669-FCB6-4CE9-8994-733FEB8F784FQ48136341-DFFF1852-D8FE-466D-9CF8-16A1DE9B769FQ48172992-19FC66C1-48AF-4BF4-8640-65154C488BBFQ48191965-6593E6CC-8163-4824-AA56-0AF45162D76DQ48535499-67618106-8104-44C7-9EC0-1D9FA7C7A3BFQ49315243-F5FD57EA-252D-4265-B7F7-04FEAA71DA1CQ50079201-D2140FFC-8612-4C59-BF84-B4A6F6AAFD79Q50237402-20B01DEC-6F0E-4A17-90B3-739D3A9AB4C7Q50279083-7363EFDE-B9A7-46BB-BE7F-070CA0592135Q50713607-5EBBEC60-93A1-4E2E-BA4F-53926EBE413DQ51158618-766D6C9A-115A-4AF7-A7F3-55FD9B3F9E19Q52561556-FC406C8D-356F-48E4-9B1C-7ADF3AC16980
P2860
Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Systematic review with meta-an ...... anti-TNF treatment has failed.
@en
type
label
Systematic review with meta-an ...... anti-TNF treatment has failed.
@en
prefLabel
Systematic review with meta-an ...... anti-TNF treatment has failed.
@en
P2860
P50
P921
P356
P1476
Systematic review with meta-an ...... anti-TNF treatment has failed
@en
P2093
A G McNicholl
P2860
P304
P356
10.1111/APT.13083
P407
P577
2015-02-04T00:00:00Z